Forbes

Walmart this spring will roll out clinical research sites in a limited number of stores and former shuttered clinic sites in an effort to increase patient access.

PBM transparency reforms aim to lower drug costs, but their impact on competition depends on how they affect smaller and independent pharmacy benefit managers.

End of life decision making is not just about living wills. More important than specifying what you want is specifying who you want making decisions.

Daniel Nadler, the 42-year-old CEO and cofounder of OpenEvidence, is now worth $7.6 billion as his AI search tool surges in popularity among U.S. doctors.

In this week’s edition of InnovationRx, we look at why Yann LeCun’s AI startup is focused on healthcare, Epic’s new predictive tools, and more.

Measles is revealing fractures in our public health system and insurance disparities. Each case costs almost $250,000. Misinformation about vaccine safety is fueling the rise.

Electronic retinal implants such as the PRIMA system bypass damaged cells to restore partial central vision, bringing high‑tech artificial sight closer to everyday clinical reality.

Alex LeBrun, cofounder of medical scribe startup Nabla who LeCun hired to be the CEO of Advanced Machine Intelligence, thinks the startup’s new AI models could start to roll out in a year, with healthcare a major focus area.

Course correction in healthcare is inherently slow. And by the time leaders act, threats often become too large to reverse.

Hospital merger and acquisition activity ended 2025 with momentum expected to continue as drastic cuts to Medicaid spending under Trump’s One Big Beautiful Bill Act loom.

No gene acts alone: interacting variants and protein partnerships can worsen, mask or even rescue disease risk, demanding multidimensional, context‑aware models of genetic prediction.

The new 2025-2030 Dietary Guidelines for Americans issued by the USDA/HHS features red meat and beef tallow quite prominently. Here's the lowdown on how to view them.